Press release
September 29, 2025
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Neuphoria Therapeutics Inc. (NEUP)
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc.